217 related articles for article (PubMed ID: 32572522)
1. Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma.
Nagayama T; Ashizawa M; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2020 Dec; 99(12):2893-2901. PubMed ID: 32572522
[TBL] [Abstract][Full Text] [Related]
2. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
3. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
[TBL] [Abstract][Full Text] [Related]
4. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
Ding X; Huang W; Peng Y; Fan H; Zhu Y; Liu X; Yang Y; Guo Q; Qiu L; Dai Y; Zou D; Jin F
Ann Hematol; 2020 Jun; 99(6):1331-1339. PubMed ID: 32382775
[TBL] [Abstract][Full Text] [Related]
5. Adequate Engraftment With Lower Hematopoietic Stem Cell Dose.
Jeyaraman P; Borah P; Dayal N; Pathak S; Naithani R
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):260-263. PubMed ID: 32019732
[TBL] [Abstract][Full Text] [Related]
6. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.
Gunn N; Damon L; Varosy P; Navarro W; Martin T; Ries C; Linker C
Biol Blood Marrow Transplant; 2003 Oct; 9(10):643-8. PubMed ID: 14569560
[TBL] [Abstract][Full Text] [Related]
7. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang EC; Muffly LS; Shiraz P; Shizuru JA; Johnston L; Arai S; Frank MJ; Weng WK; Lowsky R; Rezvani A; Meyer EH; Negrin R; Miklos DB; Sidana S
Transplant Cell Ther; 2021 May; 27(5):405.e1-405.e6. PubMed ID: 33775587
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Gu J; Liu J; Li X; Zou W; Huang B; Chen M; Li J
Cancer Med; 2021 Nov; 10(21):7641-7649. PubMed ID: 34569193
[TBL] [Abstract][Full Text] [Related]
9. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
11. The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma.
Martin RMG; Ricci MJ; Foley R; Mian HS
Transfus Apher Sci; 2017 Aug; 56(4):552-557. PubMed ID: 28669690
[TBL] [Abstract][Full Text] [Related]
12. Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation.
Sartor MM; Garvin F; Antonenas V; Bradstock KF; Gottlieb DJ
Bone Marrow Transplant; 2007 Nov; 40(9):851-7. PubMed ID: 17704793
[TBL] [Abstract][Full Text] [Related]
13. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma.
Kim Y; Kim SJ; Cheong JW; Cho H; Chung H; Lee JY; Jang JE; Min YH; Kim JS
Hematol Oncol; 2017 Dec; 35(4):465-471. PubMed ID: 27440113
[TBL] [Abstract][Full Text] [Related]
15. Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma.
Yamaguchi J; Chinen Y; Takimoto-Shimomura T; Nagata H; Muramatsu A; Kuriyama K; Ohshiro M; Hirakawa Y; Iwai T; Uchiyama H; Uoshima N; Kaneko H; Nakao M; Tsukamoto T; Shimura Y; Kobayashi T; Horiike S; Yokota I; Kuroda J;
Leuk Lymphoma; 2019 Dec; 60(14):3434-3441. PubMed ID: 31318305
[TBL] [Abstract][Full Text] [Related]
16. Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery.
Ungerstedt JS; Watz E; Uttervall K; Johansson BM; Wahlin BE; Näsman P; Ljungman P; Gruber A; Axdorph Nygell U; Nahi H
Med Oncol; 2012 Sep; 29(3):2191-9. PubMed ID: 21779930
[TBL] [Abstract][Full Text] [Related]
17. Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma.
Okada Y; Kimura F; Kurita N; Takahashi H; Shimazu Y; Mizuno S; Uchida N; Kataoka K; Hiramoto N; Ota S; Kako S; Tsukada N; Kanda Y; Kurahashi S; Doki N; Nishikawa A; Kim SW; Hangaishi A; Kanda J; Fukuda T; Atsuta Y; Kondo E; Kawamura K; Nakasone H
Cytotherapy; 2023 Nov; 25(11):1212-1219. PubMed ID: 37354150
[TBL] [Abstract][Full Text] [Related]
18. Role of the CD34+ 38- cells in posttransplant hematopoietic recovery.
Hénon P; Sovalat H; Bourderont D; Ojeda-Uribe M; Arkam Y; Wunder E; Raidot JP; Husseini F; Audhuy B
Stem Cells; 1998; 16 Suppl 1():113-22. PubMed ID: 11012153
[TBL] [Abstract][Full Text] [Related]
19. Influence of laboratory procedures on postthawing cell viability and hematopoietic engraftment after autologous peripheral blood stem cell transplantation.
Belisário AR; da Costa Funes AP; Luz JR; de Almeida Costa L; Furtado MDSBS; Martins MC; Cruz NG; Pederzoli PRMP; de Andrade RK; Libânio MRIS; de Lima Prata K
Transfusion; 2021 Apr; 61(4):1202-1214. PubMed ID: 33569783
[TBL] [Abstract][Full Text] [Related]
20. Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products.
Hermouet S; Niaussat AE; Briec A; Pineau D; Robillard N; Bataille R; Milpied N; Harousseau JL; Mahé B
Hematol Cell Ther; 1997 Dec; 39(6):317-25. PubMed ID: 9497891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
